Envestnet Asset Management
RNTX

Envestnet Asset Management’s Rein Therapeutics RNTX Stock Holding History

Envestnet Asset Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-9,201
Closed -$38K – 4090
2022
Q3 		$38K Buy
9,201
+3,182
+53% +$13.4K ﹤0.01% 3828
2022
Q2 		$31K Buy
6,019
+16
+0.3% +$147 ﹤0.01% 3858
2022
Q1 		$62K Sell
6,003
-835
-12% -$7.56K ﹤0.01% 3845
2021
Q4 		$77K Buy
6,838
+4,129
+152% +$63.9K ﹤0.01% 3784
2021
Q3 		$55K Buy
2,709
+976
+56% +$21.4K ﹤0.01% 3633
2021
Q2 		$43K Buy
1,733
+539
+45% +$13.4K ﹤0.01% 3608
2021
Q1 		$34K Buy
1,194
+612
+105% +$21K ﹤0.01% 3465
2020
Q4 		$12K Buy
+582
New +$14.5K ﹤0.01% 3260

Other funds holding RNTX

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Envestnet Asset Management's RNTX Position: Q4 2022 in Review

Envestnet Asset Management sold out of Rein Therapeutics (RNTX) in Q4 2022, closing a stake of 9,201 shares — an estimated $38K sold.

Envestnet Asset Management first reported a position in RNTX in Q4 2020 and held it in 8 quarters. The position peaked at $77K in Q4 2021. 19 funds tracked by Wall St. Rank hold RNTX as of Q4 2022.

  • Envestnet Asset Management reported no remaining Rein Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Envestnet Asset Management sold 9,201 Rein Therapeutics shares in Q4 2022, an estimated $38K.
  • Envestnet Asset Management first reported a position in Rein Therapeutics in Q4 2020 and held it in 8 quarters.
  • Envestnet Asset Management's Rein Therapeutics position peaked at $77K in Q4 2021.
  • 19 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2022.

Based on Envestnet Asset Management's 13F filing for Q4 2022, filed 7 Feb 2023.